Intensity Therapeutics
INTS
27 hedge funds and large institutions have $607K invested in Intensity Therapeutics in 2025 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 4 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
29% more funds holding
Funds holding: 21 → 27 (+6)
0.38% less ownership
Funds ownership: 0.68% → 0.3% (-0.38%)
88% less capital invested
Capital invested by funds: $5.1M → $607K (-$4.49M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SL
Sentinus LLC
Oak Brook,
Illinois
|
+$141K |
| 2 |
MFIM
Mesirow Financial Investment Management
Chicago,
Illinois
|
+$57.5K |
| 3 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$56.2K |
| 4 |
Jane Street
New York
|
+$36.9K |
| 5 |
HF
HRT Financial
New York
|
+$20.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.72M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$156K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$50.8K |
| 4 |
BlackRock
New York
|
-$43K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$3.82K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of America
Charlotte,
North Carolina
| $119 | +$267 | +13 | +433% |
|
27
Fidelity Investments
Boston,
Massachusetts
| $31 | +$82 | +4 | New |
|
|
AC
28
Armistice Capital
New York
| – | -$1.72M | -34,902 | Closed |
|
|
29
Citadel Advisors
Miami,
Florida
| – | -$50.8K | -1,032 | Closed |
|
|
30
BlackRock
New York
| – | -$43K | -873 | Closed |
|
31
JP Morgan Chase
New York
| – | -$30 | -1 | Closed |
|
INTS Hedge Fund Activity: Q2 2025 in Review
27 of the 7,603 institutional investors tracked by Wall St. Rank reported a position in Intensity Therapeutics (INTS) for Q2 2025, worth a combined $607K — down 88% from $5.1M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new INTS positions and 4 closed out — a net gain of 6 holders — while 7 added to existing stakes and 2 trimmed.
The largest buyer was Sentinus LLC, adding an estimated $141K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.72M sold.
- 27 institutional investors held Intensity Therapeutics (INTS) as of Q2 2025, up from 21 in Q1 2025.
- Funds reported $607K of Intensity Therapeutics stock for Q2 2025, down 88% quarter-over-quarter.
- 10 funds opened new Intensity Therapeutics positions in Q2 2025 and 4 closed out, a net change of +6 holders.
- The largest Intensity Therapeutics buyer in Q2 2025 was Sentinus LLC, an estimated $141K added.
- The largest Intensity Therapeutics seller in Q2 2025 was Armistice Capital, an estimated $1.72M sold.
Based on aggregated 13F filings for Q2 2025.